CASI Pharmaceuticals, Inc.
CASIF
—
Price unavailable
7
Visible periods
7
Metrics
Peer-ranked
Benchmarks
Price Chart
36
Health
Weak
Moderately Bearish
auto_awesome
Analytical Summary
CASI Pharmaceuticals, Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.
Market Cap
—
Dividend Yield
—
Revenue Growth
—
Op. Margin
—
ROIC
—
FCF / Share
—
Trailing P/E
—
Price / Book
—
FCF Yield
—
Debt / Equity
—
info
Valuation on last close.
trending_up
Bullish Indicators
- Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning
Bearish Risks
- Operating Margin (%)Operating Margin (%) is in the bottom quartile
- Profit Margin (%)Profit Margin (%) is in the bottom quartile
Health Breakdown
Profitability ↓
1
Returns
100
Financial Health ↑
1
Cash Quality ↓
37
Financial view
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
Is the balance sheet risky?
2 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ |
|---|---|---|---|---|---|---|---|
| Debt to Equity (x) | — | — |
0.78x
Fair
Fair
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+30%)
|
— | — | — | — |
| Net Debt (USD) | $-5.63M | $-13.47M | $1.81M | $-47.11M | $-38.70M | — | — |
How resilient is the balance sheet?
3 metrics
| Metric | Q4 FY2025 Dec 31, 2025 20-F ↗ | Q4 FY2024 Dec 31, 2024 20-F ↗ | Q4 FY2023 Dec 31, 2023 20-F ↗ | Q4 FY2022 Dec 31, 2022 20-F ↗ | Q4 FY2021 Dec 31, 2021 20-F ↗ | Q4 FY2020 Dec 31, 2020 20-F ↗ | Q4 FY2019 Dec 31, 2019 20-F ↗ |
|---|---|---|---|---|---|---|---|
| Working Capital (USD) | $-36.21M | $3.12M | $42.62M | $56.42M | $48.78M | — | — |
| LT Debt (USD) | — | — | $18.89M | — | — | — | — |
| Total Equity (USD) | $-37.28M | $1.85M | $24.16M | $44.57M | $84.50M | $81.54M | $73.00M |
⌨️ Keyboard Shortcuts
/ Search
Esc Clear
A Annual
Q Quarterly
1-7 Jump to category
R Reset
Secondary lens
Benchmark Lens
Compare CASIF against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare CASIF against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for CASIF
Bullish
1
Return on Common Equity (%)
128.9%
Return on Common Equity (%) is in the top quartile
Bearish
2
Operating Margin (%)
-217.3%
Operating Margin (%) is in the bottom quartile
Profit Margin (%)
-232.0%
Profit Margin (%) is in the bottom quartile
Percentile Rankings
How CASIF compares to all companies
Return on Common Equity (%)
128.9%
Top 5%
Peers: Top 0%
Profit Margin (%)
-232.0%
Bottom 25%
Peers: Top 77%
Operating Margin (%)
-217.3%
Bottom 25%
Peers: Top 76%
Peer Comparison
CASIF vs similar peers
Return on Common Equity (%)
CASIF
128.9%
#None of 118
QTTB
71.0%
ABEO
44.7%
XOMA
37.8%
Peer median: -49.21
Profit Margin (%)
CASIF
-232.0%
#None of 26
XOMA
60.8%
QTTB
55.5%
SIGA
24.6%
Peer median: -21.61
Debt to Equity
CASIF
—
#None of 34
BIOA
0.00x
ABUS
0.00x
RANI
0.00x
Peer median: 0.19
Operating Margin (%)
CASIF
-217.3%
#None of 25
QTTB
31.5%
SIGA
25.1%
ELTP
23.3%
Peer median: -29.35
Compare CASIF with peers
Stack CASIF against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 4 days ago 7 years · 7 quarters